WO2005034967A1 - Composition pharmaceutique ou cosmetique pour traiter la peau - Google Patents

Composition pharmaceutique ou cosmetique pour traiter la peau Download PDF

Info

Publication number
WO2005034967A1
WO2005034967A1 PCT/DE2004/002220 DE2004002220W WO2005034967A1 WO 2005034967 A1 WO2005034967 A1 WO 2005034967A1 DE 2004002220 W DE2004002220 W DE 2004002220W WO 2005034967 A1 WO2005034967 A1 WO 2005034967A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical
cosmetic composition
composition according
skin
weight
Prior art date
Application number
PCT/DE2004/002220
Other languages
German (de)
English (en)
Inventor
Hans-Joachim Lach
Klaus Buchholz
Original Assignee
Hans-Joachim Lach
Klaus Buchholz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hans-Joachim Lach, Klaus Buchholz filed Critical Hans-Joachim Lach
Publication of WO2005034967A1 publication Critical patent/WO2005034967A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair

Definitions

  • composition for the treatment of the skin comprising
  • the present invention relates to a pharmaceutical or cosmetic composition for the treatment, care and / or protection of the skin.
  • the present invention relates to a topically administrable composition which is suitable for the prevention, reduction and regeneration of skin damaged by dermatoses.
  • the skin is built up in several layers so that the skin can fulfill its diverse tasks. In each layer there are typical cell structures that fulfill the corresponding functions.
  • the lowest layer of skin the so-called subcutis (subcutis)
  • the middle layer of skin the so-called dermis (corium) consists of connective tissue and contains nerves, sebaceous glands and hair. The dermis is well supplied with blood.
  • the uppermost layer of skin, the so-called epidermis is the "protective barrier" of humans against their environment. Cells are constantly being formed in the epidermis. These cells then migrate to the surface of the skin and "horn".
  • the top layer of the skin thus consists of a layer of coreless "dead” skin cells, the so-called cornea.
  • the cornea takes on the "barrier function" of the skin.
  • On the corneal layer is the so-called “protective acid mantle” of the skin, better the water-fat film (hydro-lipid film) of the skin. This consists of water and fats (lipids).
  • the water-fat film together with the water-binding substances in the The top layer is an important protection against drying out of the skin. If the skin is degreased, the water-binding substances of the cornea can be easily washed out, which leads to drying out of the skin. Thanks to its protective acid mantle, the skin acts actively against the ingress of foreign germs.
  • the skin has the ability to reabsorb certain active ingredients and it supports the regulation of circulation and body heat through its blood circulation. By eliminating sweat, it prevents the body from overheating.
  • the slightly acidic pH value of the water-fat film at pH 5-6 also repels germs.
  • the water-fat film of the skin also offers a limited balancing function against external acids and alkalis.
  • Maintaining the barrier function of the cornea is of crucial importance for humans. Is the barrier function of the skin disturbed, e.g. Exposure to solvents (degreasing the skin) or prolonged contact with water (swelling of the skin) can lead to skin diseases.
  • the subject of more recent studies on the epidermal barrier is the question of which signals convey an increase in the activity of the enzymes, cholesterol, fatty acid and ceramide synthesis after a disturbance in the barrier.
  • a possible signal for the restoration of the barrier function is a reduced water content of the cornea or an increased TEWL.
  • Disorders of essential fatty acid metabolism (EFA) provide important information about biochemical processes in the epidermis. For example, the linoleic acid deficiency not only affects the TEWL, but also the ultrastructure of the cell. Already in 1929 it was observed that a dietary deficiency in EFA leads to characteristic symptoms that resemble dry skin.
  • NMF moisturizing factors
  • dry skin is caused by the following metabolic disorders:
  • the dry skin is sensitive, rough, tight, itchy and prone to redness and flaking.
  • Dermatoses that are associated with dry skin include atopic eczema, ichthyoses, pomade crust, palmoplantar keratoses, psoriasis, etc.
  • the aim of the therapies for the damaged skin is a rapid improvement with an optimal benefit-risk ratio.
  • the factors that cause and maintain skin damage should be eliminated, such as repeated and prolonged contact with hot water, detergents or solvents.
  • DE 43 22 395 describes a shower lotion for the treatment and care of dry skin, which contains 15-35% by weight urea, 20-35% by weight glycerin, 5-20% by weight fats or fat-like substances and water as the remainder to 100%.
  • DE 298 19 234 describes an ointment formulation for the treatment of dry skin which contains 5-7% by weight urea, 1-5% by weight vitamin A acetate or vitamin E palmitate, 5-15% by weight fat / oils, 30% by weight .% purified water and Ungentum Cordes ad. Contains 100% by weight and the ointment has a pH of 5.5-7.0.
  • EP 0 598 365 describes an agent for the treatment of atopic eczema and other inflammatory skin diseases. Agents of this type contain at least 0.5% by weight of gamma-linolenic acid as an effective ingredient and additionally magnesium salts.
  • DE 4432 633 describes a pharmaceutical preparation for the local treatment of psoriasis, neurodermatitis based on omega-3 fatty acid and vitamin E as an oxidizing agent.
  • US 6,479,058 describes a composition for the treatment of skin diseases which contains corticosteroids.
  • US 2002/0048603 describes a hydrogel composition for application to the skin which comprises two or more gelling agents in the aqueous phase.
  • the gelling agents form a co-polymer network.
  • the compositions may further comprise crosslinking agents, hydrophilic and lipophilic additives.
  • Washing products degreases the skin, which often cannot be prevented or reduced even by adding lipids to the products.
  • the loss of horny layer moisture and the TEWL can often not be positively influenced even by adding lipids.
  • Repeated use of the products leads to damage to the epidermal barrier function of the skin. Many also refuse Patients stop using certain agents, such as glucocorticoid agents, for fear of side effects or late damage.
  • lipid-rich preparations preferably W / 0 emulsions. These preparations are disliked by users because they only soak into the skin very slowly and are therefore impractical in everyday use. For galenical reasons, they also have the disadvantage that hydrophilic substances can only be incorporated in small amounts for reasons of insufficient solubility.
  • compositions thus leave wide scope for further improvements in the effects, in particular with regard to the reduction of side effects and a combined or synergistic effect Reduction of the TEWL, improvement of the barrier function with topical administration of the composition.
  • the object of the present invention is to provide a pharmaceutical or cosmetic composition for the effective treatment of the damaged, in particular dry, skin. Furthermore, it is an object of the invention to provide a pharmaceutical or cosmetic composition for the effective treatment of the skin, which has fewer side effects, adheres well or sufficiently long to the skin in order to be able to act.
  • a pharmaceutical or cosmetic composition which comprises magnesium chloride and urea as active constituents and at least one pharmaceutically or cosmetically acceptable carrier, in particular a carrier suitable for dry and / or sensitive skin.
  • compositions according to the invention for the prevention and / or treatment of damaged, in particular dry, skin.
  • dermatoses that are associated with dry skin, such as atopic eczema, ichthyoses, pomade crust, palmoplantar keratoses, psoriasis, etc.
  • composition according to the invention improves the barrier function of the skin so strongly and thus normalizes the skin function overall that it achieves the effect of a lipid-rich W / 0 emulsion.
  • composition according to the invention has an improvement in the barrier function of the skin, while at the same time improving the water-binding capacity of the skin (FIG. 1).
  • inventive composition has no or significantly less skin irritation or irritation compared to conventional compositions for applying the skin.
  • compositions according to the invention penetrate well into the skin and do not leave an unpleasant layer of fat on the surface of the skin. It is also advantageous that the composition according to the invention is not “washed out” of the skin even with repeated washing.
  • Viscosity ranges of the composition according to the invention are, for example, in the range from 1000 to 15000 mP at 21 ° C. (measured using a Brookfield viscometer). In a preferred embodiment, the summary according to the invention has a viscosity of 1600 to 10000 mP (21 ° C.).
  • Magnesium chloride is usually used in an amount of 0.004-30% by weight, usually 0.004-14% by weight, preferably 0.01-10% by weight and very particularly preferably 0.5-5% by weight, based on the total weight of the composition, added.
  • Magnesium chloride is usually used in the form of magnesium chloride hexahydrate, but is not limited to this.
  • Urea is usually present in an amount of 0.1-30% by weight, usually 0.1-20% by weight, preferably 1-15% by weight and very particularly preferably 2-12% by weight, based on the total weight of the composition , added.
  • this in addition to magnesium chloride and urea, this also comprises evening primrose oil, preferably in an amount of 0.5 to 20% by weight, based on the total weight of the composition.
  • this additionally comprises zinc compounds, preferably selected from zinc oxide, zinc acetate, zinc D-gluconate, zinc sulfate.
  • panthenol, polidocanol, ceramides, essential fatty acids or tocopherol can be added as further active ingredients.
  • the essential fatty acids are preferably selected from the group linoleic acid, ⁇ -linolenic acid, ⁇ -linolenic acid, arachidonic acid, eicosapentaenoic acid, docohexaenoic acid. This has the advantage that wound healing is additionally accelerated, the itching is reduced, the normalization of the epidermal lipid barrier is promoted or radicals are bound.
  • compositions according to the invention are used for topical application to the skin.
  • Topical compositions are understood to mean those compositions which are suitable for applying the active ingredients to the skin in a fine distribution and preferably in a form which can be absorbed by the skin. Suitable for this purpose are, for example, aqueous and aqueous-alcoholic solutions, sprays, foams, foam aerosols, ointments, aqueous gels, emulsions of the O / W or W / O type, microemulsions or cosmetic stick preparations.
  • the pharmaceutically or cosmetically acceptable carrier used in the composition according to the invention is water, a water-based liquid, an oil or fat, a gel, an emulsion or microemulsion, a dispersion or a mixture thereof.
  • the carrier used has good skin tolerance. They should be absorbed quickly and at the same time provide the skin with sufficient amounts of the active ingredients without leaving the user feeling "sticky.” Aqueous gels, emulsions or microemulsions are particularly advantageous for topical compositions.
  • the following lipophilic components can be selected, for example: oils, such as evening primrose oil, borage oil, jojoba oil, wheat germ oil, olive oil, avocado oil, almond oil, shea butter, shore butter, hydrogenated castor oil - usual fats or fatty acid esters, such as cetearyl alcohol, cetyl palmitate, decyl oleate, glyceryl caprylate, laurate, stearate, stearate citrate, lanolin alcohol, myristillactate, sorbitol, succrosecocoate etc.
  • oils such as evening primrose oil, borage oil, jojoba oil, wheat germ oil, olive oil, avocado oil, almond oil, shea butter, shore butter, hydrogenated castor oil - usual fats or fatty acid esters, such as cetearyl alcohol, cetyl palmitate, decyl oleate, glyceryl caprylate, laurate, stearate, stearate citrate, lanolin alcohol, myristill
  • the lipophilic constituents are preferably used in an amount of 5 to 50% by weight, based on the total weight of the composition, and particularly preferably 12 to 25% by weight.
  • compositions according to the invention are advantageously used in pH-buffered preparations, a pH range of 4-7 being preferred and very particularly preferably the range of about 5-6.
  • citric acid or ascorbic acid can be used to adjust the pH range.
  • composition according to the invention can comprise further optional components.
  • Nonionic surfactants, zwitterionic surfactants, ampholytic surfactants or anionic emulsifiers can be used as emulsifiers.
  • the emulsifiers can be present in the composition according to the invention in amounts of 0.1 to 40% by weight, usually 1 to 30% by weight and preferably 4 to 20% by weight, based on the total weight of the cosmetic compositions.
  • a surfactant from at least one of the following groups can be used as the nonionic surfactant:
  • Partial esters based on linear, branched, unsaturated or saturated C6 / 22 fatty acids, ricinoleic acid and 12-hydroxystearic acid and glycerol, polyglycerol, pentaerythritol, dipentaerythritol, sugar alcohols (e.g. sorbitol), alkyl glucosides (e.g. methyl glucoside, Butyl glucoside, lauryl glucoside) and polyglucosides (e.g. cellulose);
  • the emulsifier system used in the composition according to the invention is an ethylene oxide-free emulsifier system based on vegetable raw materials.
  • Emulsifier systems based on sucrose stearates and / or polyglyceryl stearates with glucosides have proven to be particularly suitable for this.
  • sugar surfactants which are produced on the basis of renewable raw materials, are particularly preferred because they are non-toxic, biodegradable and are still skin-friendly and moisturizing even in high concentrations. This is particularly advantageous when applied to damaged skin and leads to a pleasant feeling on the skin for the user and consequently to a better "compliance".
  • sugar surfactants are cetearyl glycosides, Cocoglycosides, laurylglycosides, sorbitan stearates, sucrose cocoates, sucrose distearates, sucrose laurates, sorbitol and in particular polyglyceryl-3-methylglucose distearate, polyglyceryl-3-methylcellulose distearate or polyglyceryl-6-stearate.
  • Zwitterionic surfactants can also be used as emulsifiers.
  • Zwitterionic surfactants are those surface-active compounds which carry at least one quaternary ammonium group and at least one calboxylate or sulfonate group in the molecule.
  • Particularly suitable zwitterionic surfactants are the so-called betaines such as the N-alkyl-N, N-dimethylalmnonium glycinate, for example the cocoalkyldimethylammonium glycinate, N-acylamino-propyl-N, N-dimethyiammonium glycinate, for example the cocoacylaminopropyldimethylammonium glycinate, and 2- Alkyl-3-carboxylmethyl-3-hydroxyethylimidazoline, each having 8 to 18 carbon atoms in the alkyl or acyl group, and the cocoacylaminoethylhydroxyethylcarboxymethylglycinate.
  • betaines such as the N-alkyl-N, N-dimethylalmnonium glycinate, for example the cocoalkyldimethylammonium glycinate, N-acylamino-propyl-N, N-dime
  • Suitable emulsifiers are ampholytic surfactants.
  • Ampholytic surfactants are surface-active compounds which, in addition to a C1 / 18-alkyl or -acyl group, contain at least one free amino group and at least one -COOH or -SO 3 H group in the molecule and are capable of forming internal salts.
  • ampholytic surfactants are N-alkylglycine, N-alkylpropionic acid, N-alkylaminobutyric acid, N-alkyliminodipropionic acid, N-hydroxyethyl-N-alkylamidopropylglycine, N-alkyltaurine, N-alkylsarcosine, 2-alkylaminopropionic acid and alkylaminoacetic acid each with about 8 to 18 C. - atoms in the alkyl group.
  • Particularly preferred ampholytic surfactants are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate and C12 / 18-acylsarcosine.
  • quaternary emulsifiers are also suitable, those of the esterquat type, preferably methyl-quaternized difatty acid triethanolamine ester salts, being particularly preferred.
  • alkyl ether sulfates, monoglyceride sulfates, fatty acid sulfates, sulfosuccinates and / or ether carboxylic acids can be used as anionic emulsifiers.
  • compositions according to the invention can contain emulsifiers in an amount of 2-23% by weight, based on the total weight of the composition.
  • the composition contains emulsifiers in an amount of 4-20% by weight. based on the total weight of the Composition, in another preferred embodiment 2-15% by weight based on the total weight of the composition.
  • Compositions with emulsifiers in an amount of 2-5% by weight, based on the total weight of the composition are particularly preferred.
  • the pharmaceutical or cosmetic composition according to the invention can contain further constituents such as, for example, caring substances, further cosmetic active substances and / or auxiliaries and additives.
  • Stabilization and / or improvement of the chemical, pharmaceutical, cosmetic, application technology and / or optical properties of the composition are suitable.
  • These can be, for example, preservatives, antioxidants, plant extracts, polysaccharides, alpha hydroxy acids, complexing and sequestering agents, vitamins, perfumes, dyes, pigments, thickeners.
  • antioxidants are vitamin E (tocopherol); Ascorbyl palmitate, ascorbic acid, butylhydroxy-toluene (BHT), butylhydroxy-anisole (BHA), Na or K hydrogen sulfite, glutathione.
  • suitable polysaccharides are glucosides and cellulose and starch derivatives.
  • compositions according to the invention also contain water.
  • compositions were prepared and applied to a trial group of 8-9, non-disclosureists.
  • Cetiol V 4.00% by weight
  • Panthenol 0.35% by weight
  • Polidokanol 0.50% by weight antioxidant, preservative, buffer, emulsifier,
  • the test was carried out as a half-side comparison (untreated versus treated skin) on the forearms.
  • Disodium cocoamphodiacetate 10.00% by weight sodium lauryl ether sulfate: 20.00% by weight Lauryl glucoside: 4.00% by weight
  • Panthenol 0.35% by weight
  • Panthenol 0.35% by weight
  • Polidokanol 0.50% by weight antioxidant, preservative,
  • test subjects rated the shampoo (ES) according to the invention as follows: ES better than SS 2 patients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique ou cosmétique pour traiter, soigner et/ou protéger la peau, comprenant comme principes actifs du chlorure de magnésium et de l'urée, ainsi qu'au moins un excipient acceptable d'un point de vue pharmaceutique ou cosmétique. L'invention concerne en particulier une composition pour application topique qui convient à la prévention et à la minimisation des dermatoses, et à la régénération de la peau abîmée par des dermatoses. L'invention a également pour objet l'utilisation de cette composition pour traiter des dermatoses dues à une sécheresse cutanée.
PCT/DE2004/002220 2003-10-10 2004-10-06 Composition pharmaceutique ou cosmetique pour traiter la peau WO2005034967A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2003147824 DE10347824B4 (de) 2003-10-10 2003-10-10 Pharmazeutische oder kosmetische Zusammensetzung zur Behandlung der Haut
DE10347824.8 2003-10-10

Publications (1)

Publication Number Publication Date
WO2005034967A1 true WO2005034967A1 (fr) 2005-04-21

Family

ID=34428414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2004/002220 WO2005034967A1 (fr) 2003-10-10 2004-10-06 Composition pharmaceutique ou cosmetique pour traiter la peau

Country Status (2)

Country Link
DE (1) DE10347824B4 (fr)
WO (1) WO2005034967A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049402A2 (fr) * 2006-10-22 2008-05-02 Rudy Susilo Vernis à ongles à usage cosmétique et médical
WO2008049401A2 (fr) * 2006-10-22 2008-05-02 Rudy Susilo Vernis à ongles à usage cosmétique et médical
EP1932913A1 (fr) 2006-12-11 2008-06-18 Roche Diagnostics GmbH Isolation d'acide nucléique utilisant du polidocanol et des dérivés
CN102776173A (zh) * 2006-12-11 2012-11-14 霍夫曼-拉罗奇有限公司 使用聚多卡醇和衍生物的核酸分离

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008020797A1 (de) 2008-04-22 2009-10-29 Aquyo Cosmetics Gmbh Hautcreme und deren Verwendung zur Pflege/Behandlung und/oder zur Prophylaxe von Hautschäden vorrangig an den Füßen von Diabetikern
CN114025736A (zh) * 2019-07-09 2022-02-08 宝洁公司 局部用头皮护理组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512978A (en) * 1980-01-24 1985-04-23 Inwood Louis R Dermatological composition useful in the treatment of psoriasis
EP0155344A2 (fr) * 1983-08-02 1985-09-25 Blendax GmbH Composition pour les soins de la peau
EP0598365A1 (fr) * 1992-11-18 1994-05-25 WOGEPHARM GmbH Agent pour le traitement d'un eczème atopique et d'autres maladies inflammatoires de la peau
US5851556A (en) * 1995-04-10 1998-12-22 Societe L'oreal S.A. Use of a salt of an alkaline-earth metal as TNF-A or substance P inhibitor in a topical composition and composition obtained
DE19857492A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Wasserhaltige Hautschutzpräparate zur Prävention von Hautschäden

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2927900A (en) * 1951-07-10 1960-03-08 Gen Aniline & Film Corp Solid detergent composition and process for preparation thereof
US5051252A (en) * 1990-08-03 1991-09-24 Shiseido Co. Ltd. Oxidizing mixtures for hair care use
US6423323B2 (en) * 1997-08-18 2002-07-23 Stephanie Neubourg Foam skin cream, uses of the foam skin protection cream and a process for its preparation
JP2000109895A (ja) * 1998-10-01 2000-04-18 Futaba Kagaku:Kk 洗浄剤組成物
DE19857489A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Ölhaltige Hautschutzpräparate zur Prävention von Hautschäden
WO2002047726A2 (fr) * 2000-12-12 2002-06-20 Japan Tobacco Inc. Composition pharmaceutique contenant un surfactant

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512978A (en) * 1980-01-24 1985-04-23 Inwood Louis R Dermatological composition useful in the treatment of psoriasis
EP0155344A2 (fr) * 1983-08-02 1985-09-25 Blendax GmbH Composition pour les soins de la peau
EP0598365A1 (fr) * 1992-11-18 1994-05-25 WOGEPHARM GmbH Agent pour le traitement d'un eczème atopique et d'autres maladies inflammatoires de la peau
US5851556A (en) * 1995-04-10 1998-12-22 Societe L'oreal S.A. Use of a salt of an alkaline-earth metal as TNF-A or substance P inhibitor in a topical composition and composition obtained
DE19857492A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Wasserhaltige Hautschutzpräparate zur Prävention von Hautschäden

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049402A2 (fr) * 2006-10-22 2008-05-02 Rudy Susilo Vernis à ongles à usage cosmétique et médical
WO2008049401A2 (fr) * 2006-10-22 2008-05-02 Rudy Susilo Vernis à ongles à usage cosmétique et médical
WO2008049401A3 (fr) * 2006-10-22 2008-07-03 Rudy Susilo Vernis à ongles à usage cosmétique et médical
WO2008049402A3 (fr) * 2006-10-22 2008-07-17 Rudy Susilo Vernis à ongles à usage cosmétique et médical
EP1932913A1 (fr) 2006-12-11 2008-06-18 Roche Diagnostics GmbH Isolation d'acide nucléique utilisant du polidocanol et des dérivés
CN102776173A (zh) * 2006-12-11 2012-11-14 霍夫曼-拉罗奇有限公司 使用聚多卡醇和衍生物的核酸分离
EP1932913B1 (fr) * 2006-12-11 2013-01-16 Roche Diagnostics GmbH Isolation d'acide nucléique utilisant du polidocanol et des dérivés

Also Published As

Publication number Publication date
DE10347824B4 (de) 2011-08-11
DE10347824A1 (de) 2005-06-09

Similar Documents

Publication Publication Date Title
EP0934053B1 (fr) Microemulsions cosmetiques ou dermatologiques
EP0967958B1 (fr) Nettoyant corporel
DE69210515T2 (de) Kosmetisches Mittel
DE60224335T2 (de) Hautbehandlungszusammensetzung
DE69734114T2 (de) Topische zusammensetzung und verfahren zur verbesserung der lipidbarrieresynthese
WO2003105797A1 (fr) Microemulsions presentant une differentiabilite de phase binaire et de substance active, leur production et leur utilisation en particulier pour administrer de l&#39;oxygene par voie topique
EP2029089B1 (fr) Émulsion h/e pour le soin de la main
EP0877597B1 (fr) Agent nettoyant cosmetique pour la peau a base de principes actifs naturels
EP0981325B1 (fr) Produits pour le soin de la peau
DE69916695T2 (de) Verwendung mindestens eines Hydroxystilben als Mittel zur Verringerung der Adhäsion von Mikroorganismen
DE102005003708B4 (de) Verwendung von Hautpflegeöl mit Kakaobutter
DE60114272T2 (de) Verwendung von speziellen Fettsubstanzen, mit denen die physikalisch-chemischen Eigenschaften der Haut und/oder der Schleimhäute verändert werden können, als Wirkstoffe, die das Anhaften von Mikroorganismen verhindern oder vermindern
DE102006011884A1 (de) Silikonfreie Haarreinigungsemulsion
EP1721601A1 (fr) Utilisation de taurine pour augmenter la synthèse des lipides cutanés
DE60113167T2 (de) Verwendung von Verbindungen, mit denen die physikalisch-chemischen Eigenschaften der Haut und/oder der Schleimhäute verändert werden können, als Wirkstoffe, die das Anhaften von Mikroorganismen verhindern oder vermindern
DE10347824B4 (de) Pharmazeutische oder kosmetische Zusammensetzung zur Behandlung der Haut
EP1046392A2 (fr) Compositions cosmétiques et dermatologiques pour améliorer la fonction de barrièrre de la peau
DE102005008299A1 (de) Universalpflegecreme
EP1731532A1 (fr) Scléroglucane dépolymérisé destiné à la régulation et à l&#39;amélioration de l&#39;hydratation de la peau
EP4221676A1 (fr) Composition pour traiter les cheveux et la peau
WO2008046606A2 (fr) Composition topique pour le traitement d&#39;eczéma
DE4310015A1 (de) Mittel zur Pflege der menschlichen Haut
EP3236920B1 (fr) Préparation antimicrobienne comprenant des alcanes de bispyridinium, des éthers de 1- ou 2-(c1 à c24-alkyl)-glycérol et des alcane-1,2-diols
DE4130915A1 (de) Kopfhaut-feuchthaltemittel und aeusserlich anzuwendendes hautpraeparat
DE19834812A1 (de) Verwendung von Sterolderivaten in kosmetischen und dermatologischen Zubereitungen zur Stärkung der Barrierefunktion der Haut

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase